This document is Pfizer Inc.'s quarterly report, specifically a Form 10-Q filed with the U.S. Securities and Exchange Commission for the period ended June 29, 2025. It provides a comprehensive overview of the company's financial performance, including condensed consolidated financial statements such as income statements, balance sheets, and cash flow statements, along with accompanying notes explaining accounting policies, investments, and liabilities. The report also details management's discussion and analysis of financial condition and results of operations, offering insights into revenue drivers, restructuring programs, and legal contingencies, including extensive patent litigation. Furthermore, it outlines Pfizer's segment information, including Biopharma, PC1, and Pfizer Ignite, and addresses forward-looking statements and risk factors that could impact future results.
